Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 472 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CM CREATE MedicinesCompany profile Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies | $122M | Series B | Biotech | United States | Investors | |
| DT Degron TherapeuticsCompany profile Develops molecular glue degrader medicines targeting previously undruggable proteins Develops molecular glue degrader medicines targeting previously undruggable proteins | $40M | Series A+Series A | Biotech | China | Investors | |
| AG Avant GenomicsCompany profile Automates liquid biopsy sample preparation for consistent, scalable cancer DNA extraction Automates liquid biopsy sample preparation for consistent, scalable cancer DNA extraction | >$3M | Seed | Biotech | United States | Investors | |
| Q QuartzBioCompany profile Provides AI-powered sample and biomarker intelligence platform for clinical-stage biopharma Provides AI-powered sample and biomarker intelligence platform for clinical-stage biopharma | Undisclosed | Growth | Biotech, Healthtech | United States | Investors | |
| U UroMemsCompany profile Develops innovative, implantable mechatronics technology to treat stress urinary incontinence Develops innovative, implantable mechatronics technology to treat stress urinary incontinence | $60M | StrategicUndisclosed | Biotech, Healthtech | France | Investors | |
| AB Autoimmunity BioSolutionsCompany profile Genetically guided therapies targeting elevated soluble IL7 receptor levels in autoimmune disease. Genetically guided therapies targeting elevated soluble IL7 receptor levels in autoimmune disease. | $1M | Seed extensionSeed | Biotech | United States | Investors | |
| TB Tolemy BioCompany profile Develops AI-enabled platform for cell biology research to help biopharma teams interpret and optimise experimental workflows Develops AI-enabled platform for cell biology research to help biopharma teams interpret and optimise experimental workflows | €1.4M | Pre-SeedPre-seed | Biotech | United Kingdom | Investors | |
| IL Isomorphic LabsCompany profile Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas | $2.1B | Series B | Biotech | United Kingdom | Investors | |
| A AlgorithmiqCompany profile Algorithmiq develops quantum algorithms and software for research in chemistry, materials and life sciences. Algorithmiq develops quantum algorithms and software for research in chemistry, materials and life sciences. | €18M | Series B | Biotech, Developer tools | Italy | Investors | |
| N Develops nanostructured sensor chips for rapid pathogen detection in food | €2.6M | Seed | Biotech | Germany | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.